MX2018001055A - Promotores para mejorar la expresion en poxvirus. - Google Patents

Promotores para mejorar la expresion en poxvirus.

Info

Publication number
MX2018001055A
MX2018001055A MX2018001055A MX2018001055A MX2018001055A MX 2018001055 A MX2018001055 A MX 2018001055A MX 2018001055 A MX2018001055 A MX 2018001055A MX 2018001055 A MX2018001055 A MX 2018001055A MX 2018001055 A MX2018001055 A MX 2018001055A
Authority
MX
Mexico
Prior art keywords
promoters
poxviruses
enhancing expression
expression
enhancing
Prior art date
Application number
MX2018001055A
Other languages
English (en)
Inventor
Delcayre Alain
Li Zengji
Rountree Ryan
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of MX2018001055A publication Critical patent/MX2018001055A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención hace referencia a uno o más promotores y/o casetes de expresión que pueden usarse para mejorar la expresión de un gen heterólogo, tal como Brachury. En particular, el o los promotores y/o casetes de expresión mejoran la expresión de genes heterólogos como parte de un vector viral, tal como un poxvirus.
MX2018001055A 2015-07-31 2016-07-28 Promotores para mejorar la expresion en poxvirus. MX2018001055A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199681P 2015-07-31 2015-07-31
PCT/IB2016/001183 WO2017021776A1 (en) 2015-07-31 2016-07-28 Promoters for enhancing expression in poxviruses

Publications (1)

Publication Number Publication Date
MX2018001055A true MX2018001055A (es) 2018-05-17

Family

ID=57068152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001055A MX2018001055A (es) 2015-07-31 2016-07-28 Promotores para mejorar la expresion en poxvirus.

Country Status (16)

Country Link
US (1) US11753652B2 (es)
EP (1) EP3329016B1 (es)
JP (1) JP6851364B2 (es)
KR (1) KR102565284B1 (es)
CN (1) CN107922981B (es)
AU (1) AU2016303378B2 (es)
CA (1) CA2990549A1 (es)
DK (1) DK3329016T3 (es)
ES (1) ES2901468T3 (es)
HK (1) HK1254405A1 (es)
IL (1) IL256869B (es)
MX (1) MX2018001055A (es)
RU (1) RU2753884C2 (es)
SG (1) SG10202000447YA (es)
WO (1) WO2017021776A1 (es)
ZA (1) ZA201800104B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7202362B2 (ja) 2017-08-24 2023-01-11 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法
CA3086325A1 (en) 2017-12-19 2019-06-27 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
AU2019354101A1 (en) 2018-10-05 2021-04-15 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
JP2022507744A (ja) 2018-11-20 2022-01-18 バヴァリアン・ノルディック・アクティーゼルスカブ ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法
US20230190922A1 (en) 2019-11-20 2023-06-22 Bavarian Nordic A/S Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023118563A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Therapy for modulating immune response with recombinant mva encoding il-12
WO2024149832A1 (en) 2023-01-12 2024-07-18 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
ES2212795T3 (es) 1991-08-26 2004-08-01 Baxter Healthcare S.A. Virus de la viruela de las aves de corral recombinante.
AU731860B2 (en) 1996-07-25 2001-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant pox virus for immunization against tumor-associated antigens
RU2180352C2 (ru) 1999-11-24 2002-03-10 Государственный научный центр вирусологии и биотехнологии "Вектор" ФРАГМЕНТ ГЕНОМА ВИРУСА ОСПЫ КУР ШТАММА "К", СОДЕРЖАЩИЙ ГЕН ТИМИДИНКИНАЗЫ, РЕКОМБИНАНТНЫЕ ПЛАЗМИДНЫЕ ДНК pTK1FPV И pTK2FPV, СОДЕРЖАЩИЕ ЭТУ ПОСЛЕДОВАТЕЛЬНОСТЬ, И РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pINTFPV1, ОБЛАДАЮЩАЯ СПОСОБНОСТЬЮ ИНТЕГРИРОВАТЬСЯ В ГЕНОМ ВИРУСА ОСПЫ КУР
WO2005048957A2 (en) * 2003-02-20 2005-06-02 Therion Biologics Corporation Novel insertion sites in pox vectors
EP1673458A4 (en) * 2003-10-15 2007-12-12 Virax Dev Pty Ltd FOR RETROVIRUS (e.g., HIV) AND CYTOKIN-CODING POXVIRUS VECTOR
AU2008221383B2 (en) * 2007-02-28 2012-09-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
CN101775410B (zh) 2009-01-09 2011-11-16 中国人民解放军军事医学科学院军事兽医研究所 一种鸡痘病毒载体穿梭质粒及其应用
US10383924B2 (en) * 2009-04-17 2019-08-20 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
CN102321637A (zh) 2011-09-09 2012-01-18 中国人民解放军军事医学科学院军事兽医研究所 中国鸡痘病毒282e4弱毒株全基因组序列及其应用
WO2014043535A1 (en) * 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer

Also Published As

Publication number Publication date
RU2753884C2 (ru) 2021-08-24
WO2017021776A1 (en) 2017-02-09
JP6851364B2 (ja) 2021-03-31
CN107922981B (zh) 2022-02-25
BR112018002172A8 (pt) 2024-02-15
IL256869A (en) 2018-03-29
CN107922981A (zh) 2018-04-17
AU2016303378B2 (en) 2021-12-23
RU2018106643A (ru) 2019-08-28
IL256869B (en) 2022-07-01
CA2990549A1 (en) 2017-02-09
KR102565284B1 (ko) 2023-08-08
AU2016303378A1 (en) 2018-01-25
RU2018106643A3 (es) 2020-01-30
EP3329016A1 (en) 2018-06-06
US11753652B2 (en) 2023-09-12
ZA201800104B (en) 2022-04-28
DK3329016T3 (da) 2022-01-10
HK1254405A1 (zh) 2019-07-19
EP3329016B1 (en) 2021-10-20
SG10202000447YA (en) 2020-03-30
ES2901468T3 (es) 2022-03-22
KR20180033498A (ko) 2018-04-03
BR112018002172A2 (pt) 2018-09-18
US20180216134A1 (en) 2018-08-02
JP2018521651A (ja) 2018-08-09

Similar Documents

Publication Publication Date Title
MX2018001055A (es) Promotores para mejorar la expresion en poxvirus.
MX2022006652A (es) Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus.
HK1254230A1 (zh) Tat誘導的基於crispr/核酸內切酶的基因編輯
MX2018006767A (es) Composiciones y metodos para oncologia inmunologica.
MX2021005226A (es) Regulacion de expresion genica mediada por nucleasa.
MX2022013540A (es) Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica.
EP3285788A4 (en) Modulation of aav vector transgene expression
MX2019001672A (es) Composiciones de poxvirus quiméricos y usos de las mismas.
EP3186375A4 (en) NEW CAS9 PROTEINS AND GUIDING ELEMENTS FOR DNA TARGETING AND THE GENOME EDITION
MX2017016405A (es) Reguladores de nrf2.
JO3765B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18 (18hpv)
EP3741849A3 (en) Protease variants and polynucleotides encoding same
MX2021009309A (es) Modulacion de la actividad del complemento.
WO2015112896A3 (en) Methods and compositions for sequences guiding cas9 targeting
MY181175A (en) Therapeutic hpv16 vaccines
MX2015012334A (es) Metodos y composiciones para el control de malezas.
MX2016017382A (es) Metodos para preparar analogos de nucleotido sustituidos.
MX2018002319A (es) Composiciones biofarmaceuticas.
MY191539A (en) Streptococcal vaccine
PH12018500155A1 (en) Recombinant orf virus vector
IN2014MU01248A (es)
WO2018060368A3 (en) COMPOSITIONS AND METHODS FOR ENHANCING STABILITY OF TRANSGENES IN POXVIRUSES
MX369776B (es) Vectores recombinantes del virus isfahan.
MX2017009889A (es) Vacuna a base del citomegalovirus, expresando la glicoproteína del virus del ébola.
MX2017004769A (es) Elementos promotores y reguladores para mejorar la expresion de genes heterologos en celulas hospederas.